Seres Therapeutics (MCRB) Stock Forecast, Price Target & Predictions
MCRB Stock Forecast
Seres Therapeutics stock forecast is as follows: an average price target of $1.25 (represents a 127.40% upside from MCRB’s last price of $0.55) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
MCRB Price Target
MCRB Analyst Ratings
Buy
Seres Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 07, 2024 | Keay Nakae | Chardan Capital | $1.25 | $0.85 | 46.52% | 127.40% |
10
Seres Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $1.25 |
Last Closing Price | $0.55 | $0.55 | $0.55 |
Upside/Downside | -100.00% | -100.00% | 127.40% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 12, 2024 | Cowen & Co. | Buy | Buy | Hold |
Jun 07, 2024 | Oppenheimer | Outperform | Perform | Downgrade |
May 09, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Mar 06, 2024 | Chardan Capital | Buy | Buy | Hold |
Apr 28, 2023 | Chardan Capital | Buy | Buy | Hold |
Sep 07, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Jun 08, 2022 | Jefferies | - | Buy | Upgrade |
10
Seres Therapeutics Financial Forecast
Seres Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $64.00K | $310.00K | $126.47M | $-522.00K | $975.00K | $3.44M | $1.22M | $1.49M | $7.22M | $126.72M | $5.26M | $5.72M | $17.56M | $1.42M | $6.04M | $8.19M | $7.62M | $7.03M | $12.53M | $7.32M | $3.97M | $3.02M |
Avg Forecast | - | $5.88M | $6.25M | $12.50M | $268.67K | $31.00M | $-263.83K | $250.00K | $-155.00K | $1.50M | $125.67M | $1.58M | $6.00M | $7.00M | $4.54M | $8.49M | $12.25M | $28.52M | $5.86M | $6.45M | $6.06M | $7.27M | $9.54M | $8.54M | $6.24M | $6.70M | $8.13M | $15.32M | $4.37M | $3.16M |
High Forecast | - | $5.88M | $6.25M | $12.50M | $268.67K | $31.00M | $-263.83K | $250.00K | $-155.00K | $1.50M | $125.67M | $1.58M | $6.00M | $7.00M | $4.54M | $8.49M | $12.25M | $28.52M | $5.86M | $6.45M | $6.06M | $7.27M | $9.54M | $8.54M | $6.24M | $6.70M | $8.13M | $15.32M | $5.25M | $3.79M |
Low Forecast | - | $5.88M | $6.25M | $12.50M | $268.67K | $31.00M | $-263.83K | $250.00K | $-155.00K | $1.50M | $125.67M | $1.58M | $6.00M | $7.00M | $4.54M | $8.49M | $12.25M | $28.52M | $5.86M | $6.45M | $6.06M | $7.27M | $9.54M | $8.54M | $6.24M | $6.70M | $8.13M | $15.32M | $3.50M | $2.53M |
# Analysts | - | 1 | 1 | 3 | 1 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
Surprise % | - | - | - | - | - | - | - | - | -0.41% | 0.21% | 1.01% | -0.33% | 0.16% | 0.49% | 0.27% | 0.18% | 0.59% | 4.44% | 0.90% | 0.89% | 2.90% | 0.19% | 0.63% | 0.96% | 1.22% | 1.05% | 1.54% | 0.48% | 0.91% | 0.95% |
Forecast
Seres Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | 1 | 1 | 3 | 1 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
EBITDA | - | - | - | - | - | - | - | - | $-39.96M | $-47.41M | $49.52M | $-67.83M | $-65.29M | $-56.53M | $-61.55M | $-54.14M | $-53.53M | $70.45M | $-46.17M | $-33.29M | $-15.98M | $-27.97M | $-18.30M | $-17.36M | $-16.98M | $-14.53M | $-9.37M | $-21.79M | $-25.98M | $-23.74M |
Avg Forecast | - | $-4.78M | $-5.08M | $-10.17M | $-218.57K | $-25.22M | $214.64K | $-203.38K | $126.10K | $-1.22M | $-102.24M | $-1.29M | $-4.88M | $-5.83M | $-3.78M | $-44.77M | $-10.20M | $-23.74M | $-4.87M | $-24.70M | $-5.04M | $-6.05M | $-7.94M | $-17.36M | $-5.20M | $-5.58M | $-6.77M | $-11.68M | $-28.37M | $-24.82M |
High Forecast | - | $-4.78M | $-5.08M | $-10.17M | $-218.57K | $-25.22M | $214.64K | $-203.38K | $126.10K | $-1.22M | $-102.24M | $-1.29M | $-4.88M | $-5.83M | $-3.78M | $-35.82M | $-10.20M | $-23.74M | $-4.87M | $-19.76M | $-5.04M | $-6.05M | $-7.94M | $-13.89M | $-5.20M | $-5.58M | $-6.77M | $-9.34M | $-22.70M | $-19.86M |
Low Forecast | - | $-4.78M | $-5.08M | $-10.17M | $-218.57K | $-25.22M | $214.64K | $-203.38K | $126.10K | $-1.22M | $-102.24M | $-1.29M | $-4.88M | $-5.83M | $-3.78M | $-53.73M | $-10.20M | $-23.74M | $-4.87M | $-29.64M | $-5.04M | $-6.05M | $-7.94M | $-20.84M | $-5.20M | $-5.58M | $-6.77M | $-14.01M | $-34.04M | $-29.79M |
Surprise % | - | - | - | - | - | - | - | - | -316.92% | 38.96% | -0.48% | 52.70% | 13.38% | 9.70% | 16.28% | 1.21% | 5.25% | -2.97% | 9.47% | 1.35% | 3.17% | 4.62% | 2.30% | 1.00% | 3.27% | 2.61% | 1.39% | 1.87% | 0.92% | 0.96% |
Forecast
Seres Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | 1 | 1 | 3 | 1 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
Net Income | - | - | - | - | - | - | - | - | $-41.25M | $-47.85M | $46.55M | $-71.78M | $-69.28M | $-60.90M | $-66.14M | $-57.50M | $-44.92M | $68.22M | $-48.33M | $-35.47M | $-18.25M | $-30.28M | $-20.71M | $-19.88M | $-18.78M | $-16.41M | $-10.76M | $-24.33M | $-27.92M | $-25.47M |
Avg Forecast | $-26.46M | $-17.94M | $-17.55M | $-12.59M | $-30.86M | $-11.83M | $-41.84M | $-52.16M | $-75.81M | $-76.54M | $81.59M | $-83.96M | $-69.45M | $-71.02M | $-90.34M | $-46.82M | $-66.16M | $-8.25M | $-56.06M | $-26.31M | $-42.42M | $-38.74M | $-39.18M | $-19.88M | $-42.17M | $-48.70M | $-71.78M | $-13.04M | $-30.49M | $-26.63M |
High Forecast | $-26.46M | $-17.94M | $-17.55M | $-8.89M | $-22.29M | $-11.83M | $-41.84M | $-52.16M | $-62.54M | $-76.54M | $81.59M | $-83.96M | $-69.45M | $-71.02M | $-90.34M | $-37.46M | $-66.16M | $-8.25M | $-56.06M | $-21.05M | $-42.42M | $-38.74M | $-39.18M | $-15.90M | $-42.17M | $-48.70M | $-71.78M | $-10.43M | $-24.39M | $-21.31M |
Low Forecast | $-26.46M | $-17.94M | $-17.55M | $-15.56M | $-37.72M | $-11.83M | $-41.84M | $-52.16M | $-92.86M | $-76.54M | $81.59M | $-83.96M | $-69.45M | $-71.02M | $-90.34M | $-56.19M | $-66.16M | $-8.25M | $-56.06M | $-31.58M | $-42.42M | $-38.74M | $-39.18M | $-23.86M | $-42.17M | $-48.70M | $-71.78M | $-15.65M | $-36.59M | $-31.96M |
Surprise % | - | - | - | - | - | - | - | - | 0.54% | 0.63% | 0.57% | 0.85% | 1.00% | 0.86% | 0.73% | 1.23% | 0.68% | -8.27% | 0.86% | 1.35% | 0.43% | 0.78% | 0.53% | 1.00% | 0.45% | 0.34% | 0.15% | 1.87% | 0.92% | 0.96% |
Forecast
Seres Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | 1 | 1 | 3 | 1 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
SG&A | - | - | - | - | - | - | - | - | $13.18M | $19.99M | $28.05M | $22.47M | $22.40M | $18.38M | $20.34M | $18.57M | $20.51M | $19.56M | $17.45M | $11.74M | $10.60M | $7.55M | $6.49M | $6.14M | $5.78M | $5.90M | $5.57M | $7.50M | $8.78M | $8.76M |
Avg Forecast | - | $16.45M | $17.50M | $34.99M | $752.09K | $86.78M | $-738.56K | $699.83K | $-433.90K | $4.19M | $351.80M | $4.43M | $16.79M | $19.61M | $12.72M | $23.75M | $34.30M | $79.84M | $16.39M | $18.04M | $16.96M | $20.35M | $26.71M | $6.14M | $17.48M | $18.75M | $22.75M | $4.02M | $12.24M | $8.84M |
High Forecast | - | $16.45M | $17.50M | $34.99M | $752.09K | $86.78M | $-738.56K | $699.83K | $-433.90K | $4.19M | $351.80M | $4.43M | $16.79M | $19.61M | $12.72M | $23.75M | $34.30M | $79.84M | $16.39M | $18.04M | $16.96M | $20.35M | $26.71M | $7.37M | $17.48M | $18.75M | $22.75M | $4.82M | $14.69M | $10.61M |
Low Forecast | - | $16.45M | $17.50M | $34.99M | $752.09K | $86.78M | $-738.56K | $699.83K | $-433.90K | $4.19M | $351.80M | $4.43M | $16.79M | $19.61M | $12.72M | $23.75M | $34.30M | $79.84M | $16.39M | $18.04M | $16.96M | $20.35M | $26.71M | $4.91M | $17.48M | $18.75M | $22.75M | $3.21M | $9.80M | $7.07M |
Surprise % | - | - | - | - | - | - | - | - | -30.38% | 4.77% | 0.08% | 5.07% | 1.33% | 0.94% | 1.60% | 0.78% | 0.60% | 0.25% | 1.06% | 0.65% | 0.62% | 0.37% | 0.24% | 1.00% | 0.33% | 0.31% | 0.24% | 1.87% | 0.72% | 0.99% |
Forecast
Seres Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | 1 | 1 | 3 | 1 | 6 | 3 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 7 |
EPS | - | - | - | - | - | - | - | - | $-0.32 | $-0.37 | - | $-0.57 | $-0.64 | $-0.50 | $-0.72 | $-0.62 | $-0.49 | $0.74 | $-0.53 | $-0.39 | $-0.22 | $-0.36 | $-0.28 | $-0.28 | $-0.27 | $-0.23 | $-0.24 | $-0.59 | $-0.69 | $-0.63 |
Avg Forecast | $-0.17 | $-0.12 | $-0.12 | $-0.08 | $-0.20 | $-0.08 | $-0.27 | $-0.34 | $-0.50 | $-0.50 | $0.53 | $-0.55 | $-0.46 | $-0.47 | $-0.60 | $-0.52 | $-0.44 | $-0.05 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.26 | $-0.28 | $-0.28 | $-0.32 | $-0.47 | $-0.40 | $-0.83 | $-0.69 |
High Forecast | $-0.17 | $-0.12 | $-0.12 | $-0.06 | $-0.15 | $-0.08 | $-0.27 | $-0.34 | $-0.41 | $-0.50 | $0.53 | $-0.55 | $-0.46 | $-0.47 | $-0.60 | $-0.52 | $-0.44 | $-0.05 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.26 | $-0.28 | $-0.28 | $-0.32 | $-0.47 | $-0.40 | $-0.66 | $-0.55 |
Low Forecast | $-0.17 | $-0.12 | $-0.12 | $-0.10 | $-0.25 | $-0.08 | $-0.27 | $-0.34 | $-0.61 | $-0.50 | $0.53 | $-0.55 | $-0.46 | $-0.47 | $-0.60 | $-0.52 | $-0.44 | $-0.05 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.26 | $-0.28 | $-0.28 | $-0.32 | $-0.47 | $-0.40 | $-1.00 | $-0.83 |
Surprise % | - | - | - | - | - | - | - | - | 0.64% | 0.74% | 0.00% | 1.04% | 1.41% | 1.07% | 1.21% | 1.18% | 1.12% | -13.59% | 1.43% | 1.26% | 0.78% | 1.41% | 1.08% | 1.00% | 0.95% | 0.72% | 0.51% | 1.49% | 0.83% | 0.91% |
Forecast
Seres Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
NSTG | NanoString | $0.11 | $21.50 | 19445.45% | Buy |
SYRS | Syros Pharmaceuticals | $0.26 | $16.67 | 6311.54% | Buy |
FATE | Fate Therapeutics | $2.02 | $39.67 | 1863.86% | Buy |
IOVA | Iovance Biotherapeutics | $8.18 | $21.00 | 156.72% | Buy |
MCRB | Seres Therapeutics | $0.55 | $1.25 | 127.27% | Buy |
VCYT | Veracyte | $35.94 | $35.00 | -2.62% | Buy |